AUP.TO
Price:
$16.76
Market Cap:
$0
Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops and commercializes therapies to treat various diseases in the United States and China. It is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. The company is headquartered in Victoria, Canada.[Read more]
Industry
Medical - Specialties
IPO Date
2000-09-19
Stock Exchange
TSX
Ticker
AUP.TO
According to Aurinia Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current ROE is -30.14%. This represents a change of 188.26% compared to the average of -10.46% of the last 4 quarters.
The mean historical ROE of Aurinia Pharmaceuticals Inc. over the last ten years is 2.56%. The current -30.14% ROE has changed -1279.44% with respect to the historical average. Over the past ten years (40 quarters), AUP.TO's ROE was at its highest in in the December 2012 quarter at 243.82%. The ROE was at its lowest in in the December 2011 quarter at -98.75%.
Average
2.56%
Median
-44.00%
Minimum
-93.21%
Maximum
459.54%
Discovering the peaks and valleys of Aurinia Pharmaceuticals Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 156.75%
Maximum Annual ROE = 459.54%
Minimum Annual Increase = -1323.81%
Minimum Annual ROE = -93.21%
Year | ROE | Change |
---|---|---|
2020 | -25.18% | -44.38% |
2019 | -45.28% | -20.50% |
2018 | -56.96% | 33.35% |
2017 | -42.71% | -34.08% |
2016 | -64.80% | -30.48% |
2015 | -93.21% | 89.65% |
2014 | -49.15% | 156.75% |
2013 | -19.14% | -104.17% |
2012 | 459.54% | -1323.81% |
2011 | -37.55% | -34.88% |
The current ROE of Aurinia Pharmaceuticals Inc. (AUP.TO) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-42.47%
5-year avg
-46.99%
10-year avg
2.56%
Aurinia Pharmaceuticals Inc.’s ROE is
Company | ROE | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Aurinia Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Aurinia Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Aurinia Pharmaceuticals Inc.'s ROE?
How is the ROE calculated for Aurinia Pharmaceuticals Inc. (AUP.TO)?
What is the highest ROE for Aurinia Pharmaceuticals Inc. (AUP.TO)?
What is the 3-year average ROE for Aurinia Pharmaceuticals Inc. (AUP.TO)?
What is the 5-year average ROE for Aurinia Pharmaceuticals Inc. (AUP.TO)?
How does the current ROE for Aurinia Pharmaceuticals Inc. (AUP.TO) compare to its historical average?